Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half With Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound

• Oral DehydraTECH-tirzepatide Evidenced Reduced Adverse Events of 47% Compared to Injected Zepbound®
• Blood Glucose Reduction and Insulin Secretion Levels From the Oral DehydraTECH-tirzepatide Were Comparable to Injected Zepbound®

KELOWNA, BC - January 14, 2025 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®.

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%. Likewise, the injected Zepbound® resulted in 22 gastrointestinal ("GI")-related adverse events, whereas the oral DehydraTECH-tirzepatide resulted in only 10 GI-related adverse events, a reduction of 54%.  This latter finding is particularly noteworthy as unwanted GI impacts are generally the most commonly cited side effects of today's leading glucagon-like peptide-1 / glucose-dependent insulinotropic (GLP-1/GIP) drugs.

Furthermore, the oral DehydraTECH-tirzepatide evidenced a comparable overall reduction in blood glucose from baseline to the end of the 8-day total duration of observation in the Study that was statistically significant (p0.05). The mean baseline blood glucose levels (expressed in mg/dL) were 88.2±9.0 for oral DehydraTECH-tirzepatide and 87.8±11.3 for injected Zepbound®, compared to the Study-ending levels of 83.2±5.7 and 81.7±4.0 respectively.

Also, both the oral DehydraTECH- tirzepatide and the injected Zepbound® produced similarly increased levels of insulin from baseline to the end of the 8-day duration period in the Study, albeit only statistically significant (p